Mizuho Maintains Buy on Insmed, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $36 to $82.
June 07, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Insmed and significantly raises the price target from $36 to $82.
The significant increase in the price target from $36 to $82 by a reputable analyst at Mizuho is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100